Skip Navigation
Skip to contents

KMJ : Kosin Medical Journal

OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Browse articles > Author index
Search
Taek Sang Kim 13 Articles
Efficacy of intravesical gemcitabine instillation compared with intravesical Bacillus Calmette-Guérin instillation for non-muscle invasive bladder cancer
Dong Ha Kim, Taek Sang Kim, Su Hwan Kang, Seong Bin Kim
Kosin Med J. 2024;39(4):254-258.   Published online December 11, 2024
DOI: https://doi.org/10.7180/kmj.24.143
  • 559 View
  • 18 Download
Abstract PDFPubReader   ePub   
Background
Intravesical Bacillus Calmette-Guérin (BCG) instillation is the most effective treatment for reducing intravesical recurrence in non-muscle invasive bladder cancer (NMIBC). However, due to the recent global shortage of BCG, there is an increasing need for alternative treatments. This study aimed to retrospectively compare the outcomes of patients treated with intravesical gemcitabine instillation and BCG instillation as initial treatment options for NMIBC.
Methods
Seventy-eight patients with NMIBC who underwent transurethral resection of bladder tumors between January 2022 and September 2023 were reviewed. Of these, 42 patients received intravesical gemcitabine instillation, and 36 patients received BCG instillation. Recurrence-free survival (RFS) was analyzed, along with tumor multiplicity, grade, T stage, size, and bladder storage time after instillation, which could influence RFS.
Results
The mean follow-up period was 18.7 months for the gemcitabine group and 20.6 months for the BCG group. Recurrence occurred in 46.15% of patients (52.38% in the gemcitabine group and 38.92% in the BCG group). Tumor characteristics, including multiplicity, grade, stage, and size, were not significantly different between the two groups. The mean RFS was 15.92 months in the gemcitabine group and 19.84 months in the BCG group, with no statistically significant difference (p=0.397). However, gemcitabine instillation caused more severe bladder irritation, with shorter bladder storage time.
Conclusions
Intravesical gemcitabine and BCG instillation yielded comparable RFS outcomes. However, gemcitabine led to more severe bladder irritation, highlighting the need for further studies to optimize its application.
Comparison of transperitoneal and retroperitoneal robot partial nephrectomy for kidney tumors
Yongdeuk Seo, Su Hwan Kang, Taek Sang Kim, Dong Ha Kim, Seong Bin Kim
Kosin Med J. 2023;38(4):274-277.   Published online December 20, 2023
DOI: https://doi.org/10.7180/kmj.23.145
  • 1,077 View
  • 26 Download
Abstract PDFPubReader   ePub   
Background
Surgical techniques for small kidney tumors have been developed for decades, from open to robotic surgery. There are two approaches for partial nephrectomy: transperitoneal and retroperitoneal. We divided robotic partial nephrectomy cases into transperitoneal robotic partial nephrectomy (TRPN) and retroperitoneal robotic partial nephrectomy (RRPN) and compared the outcomes.
Methods
We retrospectively evaluated patients who underwent robotic partial nephrectomy at our hospital between November 2019 and May 2022. We reviewed patients’ demographic and perioperative data.
Results
Seventy robotic partial nephrectomies were performed (35 TRPN and 35 RRPN). There were significant differences in operation time, estimated blood loss (EBL), tumor size, and the RENAL Nephrometry Score (RNS) between those who underwent TRPN and those who underwent RRPN. Larger tumors were noted in the TRPN group, and the RNS was higher. In contrast, the operation time was shorter, EBL was lower, and tumors were more likely to be located in the posterior and lower portions in the RRPN group than in the TRPN group.
Conclusions
In our study, RRPN had advantages over TRPN in terms of operation time and EBL. However, TRPN tended to be performed rather than RRPN for tumors that were more complex in terms of size or RNS. Although the choice between RRPN and TRPN depends on the surgeon's preference, RRPN seems effective for treating small kidney tumors if selected appropriately.
Comparison of the prevalence and histology between primary benign bladder tumors and recurrent benign lesions after transurethral resection of malignant bladder tumors
Jae Jin Baek, Yong Deuk Seo, Dong Ha Kim, Won Tae Seo, Su Hwan Kang, Taek Sang Kim, Bong Kwon Chun
Kosin Med J. 2023;38(1):43-49.   Published online February 17, 2023
DOI: https://doi.org/10.7180/kmj.22.133
  • 3,481 View
  • 58 Download
Abstract PDFPubReader   ePub   
Background
Benign bladder tumors are rare disease entities, and insufficient studies have assessed their epidemiological characteristics. The authors investigated the prevalence of benign bladder tumors by retrospectively investigating pathology reports of transurethral resection of bladder tumor (TURBT) procedures over the past 20 years.
Methods
We analyzed 1,674 pathology reports of TURBT conducted in 1,160 patients from January 1, 2000, to April 30, 2022. The prevalence of benign tumors and histological classification according to the presence of primary (group 1) and recurrent (group 2) bladder lesions were retrospectively investigated.
Results
The mean age of patients was 65.2±11.5 years, and 1,284 cases (79.1%) were in men. Benign bladder tumors comprised 278 cases (248 patients) accounting for about 17.1% of the total TURBT cases (278/1,624). Furthermore, 184 patients (16.0%, 184/1,147) belonged to group 1 and 78 patients (27.4%, 78/285) belonged to group 2. Among all benign lesions that underwent TURBT, cystitis was the most common (41.0%, 114/278), and this rate was higher in group 2 (64/184 [34.8%] vs. 50/94 [53.2%], p<0.001). The prevalence of non-neoplastic lesions was higher in group 1 (44/184 [23.9] vs. 11/94 [11.7%], p<0.001). There was no difference in the prevalence of noninvasive urothelial neoplasms between the two groups (22/184 [12.0%] vs. 8/94 [8.5%], p=0.86).
Conclusions
The probability of benign lesions in TURBT was 17.1%, among which cystitis was the most common. When TURBT was performed for recurrent lesions, the frequency of benign tumors was higher than that of primary benign bladder tumors.
Comparative study of off-clamp, laparoscopic partial nephrectomy (OCLPN) and conventional hilar control, laparoscopic partial nephrectomy (HCLPN) for renal tumors: One-year follow-up results of renal function change
Su Hwan Kang, Hyun Yul Rhew, Taek Sang Kim
Kosin Med J. 2018;33(2):191-199.   Published online December 31, 2018
DOI: https://doi.org/10.7180/kmj.2018.33.2.191
  • 1,621 View
  • 3 Download
Abstract PDFPubReader   ePub   
Objectives

We designed the study to compare the oncologic and renal function outcomes of off-clamp, laparoscopic partial nephrectomy (OCLPN) and conventional laparoscopic partial nephrectomy (HCLPN) for renal tumors.

Methods

Between March 2008 and July 2015, 114 patients who underwent laparoscopic partial nephrectomy (LPN) of a renal neoplasm were studied. We performed LPN without hilar clamp on 40 patients (OCLPN, Group 1), and conventional LPN with hilar control and renorrhaphy on another 40 patients (HCLPN, Group 2). We retrospectively reviewed the medical records of each patient's age, sex, R.E.N.A.L. nephrometry score (RNS), operation time, complications, hospitalization period, tumor size, positive resection margin, histologic classification of tumor, pathologic stage, Fuhrman grade, estimated blood loss (EBL), warm ischemic time (WIT), and estimated glomerular filtration rate (eGFR) before and one year after surgery.

Results

There were no significant differences in age, sex, preoperative eGFR, EBL, surgical (anesthesia) time, and tumor size between the two groups. The mean eGFR was not significantly different between the OCLPN and HCLPN groups 1 month (95 and 86.2 mL/min/1.73 m2, respectively; P = 0.106), 6 months (92.9 and 83.6 mL/min/1.73 m2, respectively; P = 0.151) and 12 months (93.8 and 84.7 mL/min/1.73 m2, respectively; P = 0.077) postoperatively. The change in eGFR after one year was 3.9% in the OCLPN group and −7.9% in the HCLPN group.

Conclusions

OCLPN was superior to HCLPN in preserving renal function one year after surgery, and there was no statistically significant difference in tumor treatment results.

Clinical significance of serum neutrophil gelatinase-associated lipocalin in the early diagnosis of renal function deterioration after radical nephrectomy
Taek Sang Kim, Su Hwan Kang, Pil Moon Kang, Hongkoo Ha, Su Dong Kim, Jangho Yoon, Hyunyong Hwang
Kosin Med J. 2018;33(1):20-28.   Published online January 21, 2018
DOI: https://doi.org/10.7180/kmj.2018.33.1.20
  • 1,615 View
  • 6 Download
Abstract PDFPubReader   
Objectives

The standard metrics used to monitor the progression of acute kidney injury (AKI) include markers such as serum creatinine, blood urea nitrogen, and estimated glomerular filtration rate (eGFR). Moreover, neutrophil gelatinase-associated lipocalin (NGAL) expression has been reported to modulate oxidative stress.

Methods

We aimed to evaluate the usefulness of serum NGAL levels for monitoring renal function after radical nephrectomy (RN). We prospectively collected data from 30 patients who underwent RN. We analyzed serum NGAL and creatinine at 6 time points: preoperative day 1, right after surgery, 6 hours after surgery, postoperative day (POD) 1, POD 3, and POD 5. We compared these measurements according to the eGFR values (classified as chronic kidney disease stage III; CKD III or not) using data obtained 3 months after surgery.

Results

The mean age was 65.5 years (range, 45–77 years), and the male-to-female ratio was 2:1. At the last follow-up examination, there were 12 patients (40%) with CKD III. Using receiver operating characteristic analysis, we found that serum creatinine on POD 5 (area under the curve [AUC], 0.887; P = 0.000) and NGAL at 6 hours after LRN (AUC, 0.743, P = 0.026) were significant predictors of CKD III. The development of CKD III after LRN was associated with the serum creatinine level on POD 5 and the NGAL at 6 hours after surgery.

Conclusions

Compared to serum creatinine, serum NGAL enabled earlier prediction of postoperative CKD III. Therefore, serum NGAL measured 6 hours after surgery could be a useful marker for managing patients after RN.

Metachronous anterior urethral metastasis of prostatic ductal adenocarcinoma
Jeong Hyun Oh, Taek Sang Kim, Hyun Yul Rhew, Bong Kwon Chun
Kosin Med J. 2016;31(1):66-70.   Published online February 4, 2016
DOI: https://doi.org/10.7180/kmj.2016.31.1.66
  • 1,645 View
  • 6 Download
Abstract PDFPubReader   ePub   
Abstract

Prostate cancer is increasing in frequency in Korea. Among them, ductal adenocarcinoma (DCP) has a more aggressive and poor prognosis than acinar adenocarcinoma (ACP), despite its low incidence. Patients usually present with symptoms of lower urinary tract symptoms and hematuria due to increasing tumor mass within the lumen of the prostatic urethra, making diagnosis of DCP by the transrectal prostate biopsy difficult. DCP is often metastasized at the time of diagnosis. DCP is transferable to most other organs but the metastasis to the anterior urethra is rare. There is no doubt that localized DCP requires radical prostatectomy (RP) but the guidelines for adjuvant therapy after RP have not yet been established. Methods of the treatment are confounded by individual differences, and arriving at a consensus is challenging due to insufficient data. We report a case of DCP and urethral metastasis after RP, thus aiding in the determination of treatment guidelines.

Current Status of Laparoscopic Partial Nephrectomy
Taek Sang Kim
Kosin Med J. 2013;28(2):79-86.   Published online January 19, 2013
DOI: https://doi.org/10.7180/kmj.2013.28.2.79
  • 1,602 View
  • 6 Download
Abstract PDFPubReader   ePub   

Recently, nephron-sparing, minimally invasive surgery of small renal masses has become popular. The most typical surgery is laparoscopic partial nephrectomy (LPN). However, due to technical difficulties, the indications for LPN had been limited to small, exophytic, and peripheral tumors. This paper introduces current status of oncological outcomes and technical considerations.

Carbon Monoxide Prevents Ob-Rb Transfected Neuronal Cells from ER Stress-Induced Leption Resistance
Seong Ju Kim, Taek Sang Kim, Hyun Yul Rhew, Hun Taeg Chung
Kosin Med J. 2010;25(1):42-50.   Published online June 30, 2010
  • 484 View
  • 1 Download
PDF
Update of Targeted Molecular Therapy in Metastatic Renal Cell Carcinoma
Taek Sang Kim, Hyun Yul Rhew
Kosin Med J. 2009;24(1):110-118.   Published online June 30, 2009
  • 398 View
  • 1 Download
PDF
Therapeutical Value of Adrenalectomy in case of Metastatic Spead Originating from Primary Renal Cell Solitary Carcinoma
Han Seok Kim, Taek Sang Kim, Hyun Yul Rhew
Kosin Med J. 2007;22(1):184-189.   Published online June 30, 2007
  • 308 View
  • 1 Download
PDF
The Effect of Alfuzosin, Doxazosin, Tamsulosin and Finasteride Combination Therapy in Patients with Benign Prostatic Hyperplasia
Du Yong Kim, Han Seok Kim, Taek Sang Kim, Seong Choi, Hyun Yul Rhew
Kosin Med J. 2007;22(1):190-195.   Published online June 30, 2007
  • 399 View
  • 3 Download
PDF
Regulatory Mechanisms for the Expression of Inducible Nitric Oxide Synthase (iNOS) Gene in Rat Vascular Smooth Muscle Cells
Ho Jun An, Taek Sang Kim, Ju Seok Kang, Hyun Yul Rhew, Hun Taeg Chung
Kosin Med J. 2005;20(1):12-131.
  • 516 View
  • 1 Download
PDF

KMJ : Kosin Medical Journal
TOP